| IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 … P Paschka, RF Schlenk, VI Gaidzik, M Habdank, J Kronke, L Bullinger, ... J Clin Oncol 28 (22), 3636-3643, 2010 | 997 | 2010 |
| The target landscape of clinical kinase drugs S Klaeger, S Heinzlmeir, M Wilhelm, H Polzer, B Vick, PA Koenig, ... Science 358 (6367), eaan4368, 2017 | 736 | 2017 |
| The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML S Kayser, K Doehner, J Krauter, CH Koehne, HA Horst, G Held, ... Blood, The Journal of the American Society of Hematology 117 (7), 2137-2145, 2011 | 513 | 2011 |
| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 451 | 2020 |
| Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation RF Schlenk, S Kayser, L Bullinger, G Kobbe, J Casper, M Ringhoffer, ... Blood, The Journal of the American Society of Hematology 124 (23), 3441-3449, 2014 | 440 | 2014 |
| RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group VI Gaidzik, L Bullinger, RF Schlenk, AS Zimmermann, J Röck, P Paschka, ... Journal of Clinical Oncology 29 (10), 1364-1372, 2011 | 397 | 2011 |
| Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation … A Burchert, G Bug, LV Fritz, J Finke, M Stelljes, C Röllig, E Wollmer, ... Journal of Clinical Oncology 38 (26), 2993-3002, 2020 | 396 | 2020 |
| Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term … U Platzbecker, U Germing, KS Götze, P Kiewe, K Mayer, J Chromik, ... The Lancet Oncology 18 (10), 1338-1347, 2017 | 320 | 2017 |
| TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group VI Gaidzik, P Paschka, D Spath, M Habdank, CH Kohne, U Germing, ... J Clin Oncol 30 (12), 1350-1357, 2012 | 308 | 2012 |
| RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features VI Gaidzik, V Teleanu, E Papaemmanuil, D Weber, P Paschka, J Hahn, ... Leukemia 30 (11), 2160-2168, 2016 | 302 | 2016 |
| Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD RF Schlenk, D Weber, W Fiedler, HR Salih, G Wulf, H Salwender, ... Blood, The Journal of the American Society of Hematology 133 (8), 840-851, 2019 | 288 | 2019 |
| Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype V Grossmann, E Tiacci, AB Holmes, A Kohlmann, MP Martelli, W Kern, ... Blood, The Journal of the American Society of Hematology 118 (23), 6153-6163, 2011 | 285 | 2011 |
| Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 … U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ... The Lancet Oncology 19 (12), 1668-1679, 2018 | 284 | 2018 |
| Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid … RF Schlenk, K Döhner, S Mack, M Stoppel, F Király, K Götze, F Hartmann, ... Journal of Clinical Oncology 28 (30), 4642-4648, 2010 | 276 | 2010 |
| High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses SK Metzelder, T Schroeder, A Finck, S Scholl, M Fey, K Götze, YC Linn, ... Leukemia 26 (11), 2353-2359, 2012 | 255 | 2012 |
| Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B RF Schlenk, K Döhner, M Kneba, K Götze, F Hartmann, F Del Valle, ... haematologica 94 (1), 54, 2009 | 253 | 2009 |
| Secondary genetic lesions in acute myeloid leukemia with inv (16) or t (16; 16): a study of the German-Austrian AML Study Group (AMLSG) P Paschka, J Du, RF Schlenk, VI Gaidzik, L Bullinger, A Corbacioglu, ... Blood, The Journal of the American Society of Hematology 121 (1), 170-177, 2013 | 218 | 2013 |
| Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia RF Schlenk, S Fröhling, F Hartmann, JT Fischer, A Glasmacher, ... Leukemia 18 (11), 1798-1803, 2004 | 216 | 2004 |
| In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma K Philipp‐Abbrederis, K Herrmann, S Knop, M Schottelius, M Eiber, ... EMBO molecular medicine 7 (4), 477-487, 2015 | 210 | 2015 |
| Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies S Kayser, M Zucknick, K Doehner, J Krauter, CH Koehne, HA Horst, ... Blood, The Journal of the American Society of Hematology 119 (2), 551-558, 2012 | 194 | 2012 |
